At 5Y Capital (formerly known as Morningside Venture Capital), when others see crazy ones, we see visionaries. We believe that when great entrepreneurs who are crazy enough been trusted, they will build the world a better place.
Employees: 11-50
Investment Type: Venture Capital
Portfolio 56
| Date | Name | Website | Total Raised | Location |
| 18.03.2026 | Excalipoin... | excalipoint.com | $68.7M | China |
| 11.03.2026 | Dify: Lead... | dify.ai | $30M | United Sta... |
| 16.12.2025 | Allink Bio... | allinkbio.com | $89M | China |
| 19.07.2023 | 301 Moved ... | botinkit.com | $13M | China, Gua... |
| 07.06.2023 | Hopewell T... | hopewell-tx.com | $25M | United Sta... |
| 14.02.2023 | 芯华章科技... | x-epic.com | - | - |
| 26.06.2022 | Parametrix... | chaocanshu.cn | $100M | China, Gua... |
| 26.06.2022 | Bigo | bigo.tv | - | United Kin... |
| 26.06.2022 | 瀚博半导体... | vastaitech.com | - | China, Pud... |
| 26.06.2022 | 小冰 | xiaoice.com | - | China, Bei... |
Show more
Persons 18
| Date | First Name | Last Name | Title | Location | |||
| - | Michelle | Fu | Investor R... | linkedin.c... | - | m********u... | - |
| - | Jingyi | Ge | Associate | linkedin.c... | - | j******e@5... | - |
| - | Ken | Shi | Co-Founder | linkedin.c... | - | k****i@5yc... | - |
| - | Elwin | Yuan | Partner | linkedin.c... | - | e*******n@... | - |
| - | Cloris | You | Executive ... | linkedin.c... | - | c*******u@... | - |
| - | Richard | Liu | Investment... | linkedin.c... | - | r********u... | - |
| - | Teddy | Wang | Chief Fina... | linkedin.c... | - | t*******g@... | - |
| - | Joanna | Xue | Senior Adv... | linkedin.c... | - | j*******e@... | - |
| - | Fisher | Zhang | Partner | linkedin.c... | - | f*********... | - |
| - | Ted Xutian | Jing | Managing D... | linkedin.c... | - | t*****g@5y... | - |
Show more
Mentions in press and media 31
| Date | Title | Description |
| 04.04.2026 | Syneron Bio Fuels Innovation with $150M Investment | Syneron Bio secured $150 million in Series B financing. This major investment drives its intelligent Synova platform. The capital fuels advanced macrocyclic peptide drug discovery. It targets critical unmet needs across oncology, autoimmune... |
| 03.04.2026 | Syneron Bio Closes $150M Series B Financing | Syneron Bio, a Beijing, China-based intelligent platform-driven macrocyclic peptide drug discovery company, closed a $150m Series B financing round. The round was led by an international life-science fund, with co-lead participation from De... |
| 03.04.2026 | Syneron Bio: $150 Million Raised For Macrocyclic Peptide Drug Discovery Platform And Pipeline Advancement | Syneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development... |
| 03.04.2026 | Syneron Bio Announces Completion of $150 Million Series B Financing | BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international ... |
| 27.03.2026 | Zilliz Cloud Launches Native Cross-Region Disaster Recovery for Vector Databases | New Global Cluster and Global Endpoint capabilities deliver automated failover with near-zero downtime for enterprise AI applications REDWOOD CITY, Calif., March 27, 2026 /PRNewswire/ -- Zilliz, the company behind Milvus, the world's most w... |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 20.03.2026 | Zilliz Cloud Launches Customer-Managed Encryption Keys for Enterprise Data Sovereignty | New CMEK capability gives regulated enterprises full control over encryption keys for AI-scale vector workloads REDWOOD CITY, Calif., March 20, 2026 /PRNewswire/ -- Zilliz, the company behind Milvus, the world's most widely adopted open-sou... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| 18.03.2026 | Excalipoint Therapeutics Raises $68.7M in Seed Funding | Excalipoint Therapeutics, a Shanghai, China-based biotechnology company developing T-cell engager (TCE) therapies for cancer and autoimmune diseases, raised $68.7M in Seed funding. Backers included HSG, Apricot Capital, Yuanbio Venture Capi... |
| 16.03.2026 | Китайский AI-стартап Moonshot привлекает средства при оценке $18 млрд | Китайский стартап в сфере искусственного интеллекта Moonshot AI планирует привлечь до $1 млрд в рамках расширенного инвестиционного раунда, который может оценить компанию примерно в $18 млрд. Это более чем в четыре раза выше оценки компании... |
Show more